Inactive Instrument

Company Mirati Therapeutics

Equities

MRTX

US60468T1051

Business Summary

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Managers

Managers TitleAgeSince
President - Jan. 22
Director/Board Member - Jan. 22
Corporate Officer/Principal - Jan. 22

Members of the board

Members of the board TitleAgeSince
Director/Board Member - Jan. 22
Director/Board Member - Jan. 22
President - Jan. 22

Company contact information

Mirati Therapeutics, Inc.

3545 Cray Court

92121, San Diego

+858 332 3410

http://www.mirati.com
address Mirati Therapeutics(MRTX)

Sector

This company's sector is not yet available